Mania and Antimanic Drugs: Overview

Mania is characterized by heightened mood, expanded energy, and irritability, along with a reduced need for sleep. It represents a key phase of bipolar disorder, which involves alternating manic and depressive episodes. These symptoms can significantly impact daily functioning and require pharmacological management with mood stabilizers.

Lithium carbonate inhibits inositol monophosphatase and increases IP3 accumulation through the Gq-PLC-IP3-Ca2+ pathway. It also impacts monoamines and reduces arachidonic acid turnover. These mechanisms make it the most effective prophylactic medication for preventing both manic and depressive episodes in bipolar disorder.

Lithium causes fine hand tremors, dizziness, xerostomia, gastrointestinal distress, sedation, and weight gain, particularly when combined with antipsychotics. Because lithium has a narrow therapeutic index, toxicity can occur at concentrations above 1.5 mEq/L, requiring hemodialysis for acute toxicity at 3 mEq/L or higher.

Antipsychotic drugs like clozapine, olanzapine, and lurasidone help manage refractory and acute mania either individually or as adjunctive therapy. These medications require careful monitoring to balance efficacy with tolerability. Antipsychotic drugs therapeutic uses and side effects vary by agent and patient response in bipolar disorder treatment.

Anticonvulsants such as valproic acid compounds, carbamazepine, and lamotrigine help manage acute mania in pediatric bipolar disorder and serve as maintenance treatments. Lamotrigine specifically helps prevent depressive episodes, offering an alternative or adjunctive option to lithium and other mood stabilizers for personalized treatment.

Lithium has a very narrow therapeutic index, meaning the difference between an effective dose and a toxic dose is small. Serum lithium levels must be monitored because toxicity occurs at concentrations above 1.5 mEq/L, and severe toxicity at 3 mEq/L or higher requires emergency hemodialysis intervention.

Lithium functions as a prophylactic agent preventing episodes, while antipsychotics address acute manic symptoms and refractory cases. Anticonvulsants provide flexibility for specific presentations, such as lamotrigine for depressive prevention or valproic acid for acute pediatric mania, allowing clinicians to tailor treatment strategies to individual patient needs.